Changes in Hong Kong stocks | Most CRO concept stocks are rising, and the innovative drug boom is rising, and the volume and price of on-hand orders are rising, and global AI4S cooperation is expected to bring dividends

The Zhitong Finance App learned that most CRO concept stocks were higher. As of press release, Zhaoyan Pharmaceutical (06127) rose 6.64% to HK$28.28; Kanglong Chemical (03759) rose 3.30% to HK$31.26; Kingsley Biotech (01548) rose 3.02% to HK$41.68; and Tiger Pharmaceuticals (03347) rose 1.59% to HK$47.32.

According to news, the total amount of foreign authorized transactions for innovative drugs exceeded 120 billion US dollars this year, an increase of 36% over the previous year. Market participants pointed out that as innovative drug BD transactions continue to be active, pharmaceutical companies tend to have abundant R&D capital. In order to seize the innovative drug R&D window and guarantee project progress, pharmaceutical companies' willingness to pay for external R&D services has increased, and CRO companies are “rising in volume and price” trend. Furthermore, global AI4S cooperation is currently hot, and domestic CXOs are expected to fully benefit. On September 16, Eli Lilly TuneLab added three experimental service providers, Kingsley, Twist, and Ginkgo on the same day, and the competition to speed up the wet test verification process intensified.

Bohai Securities believes that the domestic investment and financing environment has shown a gradual recovery trend. Since 2025, there have been frequent large orders for innovative drug BD transactions, injecting sufficient capital into R&D, and demand has risen steadily; at the same time, the supply side has experienced a steady recovery in early production capacity, the price of experimental monkeys has steadily rebounded, and the bargaining power of leading companies has increased, and new orders are expected to rise sharply in volume and price. In terms of external demand, global innovative drug primary market financing has grown, leading domestic companies have established differentiated advantages in related fields, have sufficient orders on hand, some companies have raised their 2026 full-year performance guidelines, and the high prosperity of the industry has continued to be verified.